Olympus Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert White
- Full Time Employees
- 28,138
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2951 Ishikawa-machi Hachioji TY Japan 163-0914
- IPO Date
- Jan 13, 2010
- Website
- olympus.co.jp
- Similar Companies
- Business
- Olympus Corporation Olympus Corporation manufactures and distributes precision medical instruments and endoscopic systems worldwide. The company focuses primarily on its medical business, offering a comprehensive portfolio of endoscopes for gastrointestinal, respiratory, urological, surgical, and therapeutic applications; video imaging systems including the OLYSENSE platform with computer-aided detection and artificial intelligence solutions; laparoscopes; endoscopic ultrasound systems; treatment peripherals such as needles, stents, and biopsy forceps; and system integration solutions alongside medical services. Olympus Corporation operates globally across approximately 40 countries and regions from its headquarters in Tokyo, Japan, where it was founded in 1919, employing over 29,000 people with major subsidiaries like Olympus Corporation of the Americas in Pennsylvania, USA. In recent developments, Olympus Corporation entered a strategic partnership in July 2025 with Revival Healthcare Capital to co-found Swan EndoSurgical, investing at least $65 million initially—with potential up to $458 million—for an innovative endoluminal robotic system targeting less invasive gastrointestinal treatments, granting Olympus exclusive acquisition rights. The company unveiled a new corporate strategy in November 2025 to advance endoscopy-enabled care through innovation, simplification, and accountability, including global restructuring for 24 billion yen in annual savings and a net reduction of 2,000 positions while targeting 5% annual revenue growth by fiscal 2029. Additional 2025 initiatives encompass distribution agreements with W.L. Gore & Associates for EndoTherapy expansion, MacroLux Medical for single-use urology products, and launches of advanced imaging platforms for ENT and urological applications; executive appointments for respiratory innovation; and the iTind Center of Excellence program for minimally invasive prostate treatments. Olympus Corporation has divested its Life Science and Industrial Solutions segments to Evident, streamlining focus on medical technologies.
Olympus Corporation (OLYMY) Q3 2026 Earnings Call Transcript
Olympus Corporation (OLYMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Olympus Corporation (OLYMY) Discusses New Strategic Vision and Expansion of Endoscopy-Enabled Care Prepared Remarks Transcript
Olympus Corporation (OLYMY) Q1 2026 Earnings Call Transcript
Olympus Corporation (OLYMY) Q4 2025 Earnings Call Transcript
Olympus Corporation (OLYMY) Q3 2025 Earnings Call Transcript
Olympus Corporation (OLYMY) Q2 2025 Earnings Call Transcript
Olympus Corporation (OLYMY) Q1 2025 Earnings Call Transcript
Olympus Corporation (OLYMY) Q4 2024 Earnings Call Transcript
Olympus Corporation (OLYMY) Q3 2024 Earnings Call Transcript
Olympus Corporation (OCPNF) Q2 2024 Earnings Call Transcript
Olympus Corp. of the Americas to Host Panel Discussion on Lung Cancer Screening Guidelines and Eligibility
Olympus Issues Request to Discontinue Use of UHI-4 Insufflator Unit, Except in Cases Where No Alternative is Available
Olympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment
Olympus Corporation (OCPNY) Q3 2023 Earnings Call Transcript
Olympus Corporation (OCPNY) Q3 2022 Earnings Call Transcript
Why FTAC Olympus Acquisition Corp Just Jumped 10%